Last reviewed · How we verify

Histoplasmosis — Treatment Landscape & Competitive Intelligence

Histoplasmosis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Histoplasmosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Sporanox itraconazole Sebela Ireland Ltd Azole Antifungal [EPC] C-X-C chemokine receptor type 1 1992-01-01
Nizoral ketoconazole Johnson & Johnson (Janssen) Azole Antifungal [EPC] Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1 1981-06-26
Abelcet AMPHOTERICIN B Astellas Pharma Lipid-based Polyene Antifungal [EPC] 1964-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Astellas Pharma · 1 drug in Histoplasmosis
  2. Johnson & Johnson (Janssen) · 1 drug in Histoplasmosis
  3. Sebela Ireland Ltd · 1 drug in Histoplasmosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Histoplasmosis:

Cite this brief

Drug Landscape (2026). Histoplasmosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/histoplasmosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing